YAP Inhibitor
-
VT02956 hydrochloride
0 ImagesCat. No.: HY-147165AVT02956 is a LATS inhibitor (IC50: 0.76 nM for LATS1, 0.52 nM for LATS2). VT02956 targets the Hippo pathway. VT02956 inhibits ESR1 expression and growth of ER+ breast cancer cell lines and patient-derived tumor organoids. VT02956 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
-
Ki16425 (Standard)
0 ImagesSynonyms: Debio 0719 (Standard)Ki16425 (Standard) is the analytical standard of Ki16425. This product is intended for research and analytical applications. Ki16425 (Debio 0719) is a subtype-selective, competitive antagonist of the EDG-family receptors, LPA1 and LPA3 with Kis of 0.34 μM and 0.93 μM, respectively. Ki16425 (Debio 0719) reduces the LPA-induced activation of p42/p44 MAPK. Ki16425 can also inhibit LPA-induced dephosphorylation of Yes-associated protein (YAP)/TAZ in HEK293A cells.
-
IAG933 (Standard)
0 ImagesCat. No.: HY-153811RCAS No.: 2714434-21-4Synonyms: YAP-TEAD-IN-3 (Standard)IAG933 (Standard) is the analytical standard of IAG933 (HY-153811). This product is intended for research and analytical applications. IAG933 (YAP-TEAD-IN-3) is an orally available YAP/TAZ-TEAD inhibitor that has anti-tumor effects and promotes apoptosis. IAG933 YAP-TEAD-IN-3 inhibits Avi-human TEAD4217-434, with an IC50 value of 9 nM.
-
YAP/TAZ inhibitor-1 (Standard)
0 ImagesCat. No.: HY-111429RCAS No.: 2093565-23-0YAP/TAZ inhibitor-1 (Standard) is the analytical standard of YAP/TAZ inhibitor-1 (HY-111429). This product is intended for research and analytical applications. YAP/TAZ inhibitor-1 is a YAP/TAZ inhibitor extracted from patent WO2017058716A1, Compound 1, has an IC50 of <0.100 μΜ in firefly luciferase assay.
-
VT3989 (Standard)
0 ImagesCat. No.: HY-400902RCAS No.: 2506273-81-8VT3989 (Standard) is the analytical standard of VT3989 (HY-400902). This product is intended for research and analytical applications. VT3989 is an orally active pan-TEAD autopalmitoylation inhibitor that modulates the Hippo signaling pathway. VT3989 directly binds to TEAD transcription factors to block their palmitoylation modification, thereby disrupting the formation of YAP/TAZ-TEAD complexes and inhibiting downstream oncogenic transcriptional activity. VT3989 effectively inhibits the growth of NF2-deficient schwannoma and meningioma cells and reverses the Schwann cell phenotype. In addition, VT3989 exerts a synergistic effect when combined with Osimtinib (HY-15772) in EGFR-mutant non-small cell lung cancer models, significantly delaying tumor recurrence and prolonging survival. VT3989 can be used for the research of epithelioid hemangioendothelioma, malignant pleural mesothelioma, type 2 neurofibromatosis and related advanced solid tumors.
-
TEAD-IN-24
0 ImagesCat. No.: HY-180514CAS No.: 3034813-75-4TEAD-IN-24 (Example 65) is a TEAD inhibitor. TEAD-IN-24 exhibits anti-cancer activity against non-small cell lung cancer.
-
TDI-011536 (Standard)
0 ImagesCat. No.: HY-150042RCAS No.: 2687970-96-1TDI-011536 (Standard) is the analytical standard of TDI-011536 (HY-150042). This product is intended for research and analytical applications. TDI-011536 is a potent Lats Kinase inhibitor, interrupts Hippo-Yap signaling and initiates the proliferation of lesioned heartmuscle cells. TDI-011536 can be used in studies of organ conservation and regeneration.
